Bryan Selby

TL;DR: Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points.

TL;DR: In this phase 3 trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events.

TL;DR: MDV3100, a novel ARSI, significantly improves OS in men with postdocetaxel-treated CRPC reducing the risk of death by 37% relative to placebo and recommended the phase III AFFIRM trial be unblinded.

TL;DR: Use of CS at baseline was associated with reduced OS in the multivariate model, and while pts on baseline CS had worse outcomes, ENZA was consistently superior to PBO on OS, rPFS, and TTPP regardless of baseline CS use.